Cytiva helps Clover scale up biomanufacturing of COVID-19 vaccine

By The Science Advisory Board staff writers

November 16, 2020 -- Clover Biopharmaceuticals is working with Cytiva to scale up the company's COVID-19 vaccine manufacturing capabilities.

The partnership will help to accelerate the development and manufacturing of Clover's protein-based S-Trimer subunit vaccine candidate. The candidate showed promising preliminary results in a phase I clinical study, according to the company.

Clover upstream current good manufacturing practice manufacturing site in Zhejiang, China.
Clover upstream current good manufacturing practice manufacturing site in Zhejiang, China. Image courtesy of Cytiva.

Clover aims to expand the Cytivia FlexFactory capacity from 2 x 2,000 L to 4 x 2,000 L with the addition of two 2,000-L bioreactors. The factory will process equipment, services, and consumables for vaccine development in order to meet Clover's phase II/III clinical production plan as well as to reach commercial readiness should a vaccine be approved.

Clover touts positive preclinical results for COVID-19 vaccine
Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with...
CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
GE BioPharma sale to Danaher is complete
The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter